Abstract
Abstract
Background
Prostatic adenocarcinoma is the most frequent malignancy among elderly men after lung cancer, which has the second incidence and the fourth mortality rate in the Iranian population. The primary objective of this study was to investigate how single-nucleotide polymorphisms of the CDH1 gene (rs16260) and DAB2IP (rs1571801) are associated with the risk of prostate cancer through a multi-stage approach.
Results
In the first stage of the study (58 men), we compared the genotype frequency of polymorphisms rs16260 and rs1571801 in the case group to the control group to determine significant polymorphisms (P value < 0.4). No statistically significant difference was shown between the genotype frequency of rs1571801 in the case and control groups. Thus, rs1571801 polymorphism was eliminated at this stage, and only rs16260 polymorphism evaluated in the next stage. In the second stage, statistical analysis showed a significant difference between genotype frequency of rs16260 (P value = 0.037) in all participants. The effect of rs16260 on prostate cancer was not modified by age or PSA levels. Only the Gleason Score = 7 reveals a significant difference between the risk allele (A) and the allele (C) (rs16260).
Conclusions
According to the results of this study, rs16260 is associated with prostate cancer predisposition and might be used as a potential biomarker in prostate cancer. It should be noted that these results need to be confirmed in a larger population.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63
2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/364-iran-islamic-republic-of-fact-sheets.pdf
3. Nguyen-Nielsen M, Borre M (2016) Diagnostic and therapeutic strategies for prostate cancer. In: Seminars in nuclear medicine, vol 46(6). WB Saunders, pp 484–490
4. Bernal-Soriano MC, Parker LA, López-Garrigos M, Hernández-Aguado I, Caballero-Romeu JP, Gómez-Pérez L, Alfayate-Guerra R, Pastor-Valero M, García N, Lumbreras B (2019) Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: cohort study protocol. Medicine (Baltimore) 98(40):e17451. https://doi.org/10.1097/md.0000000000017451.
5. Merriel SW, Funston G, Hamilton W (2018) Prostate cancer in primary care. Adv Ther 35(9):1285–1294